LMR Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

LMR Partners’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,324	Closed	-$86.1K	–	1131
2023 Q1	$86.1K	Buy	+1,324	New	+$80.1K	﹤0.01%	952

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LMR Partners's VRCA Position: Q2 2023 in Review

LMR Partners sold out of Verrica Pharmaceuticals (VRCA) in Q2 2023, closing a stake of 1,324 shares — an estimated $86.1K sold.

LMR Partners first reported a position in VRCA in Q1 2023 and held it in 1 quarter. The position peaked at $86.1K in Q1 2023. 63 funds tracked by Wall St. Rank hold VRCA as of Q2 2023.

LMR Partners reported no remaining Verrica Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 1,324 Verrica Pharmaceuticals shares in Q2 2023, an estimated $86.1K.
LMR Partners first reported a position in Verrica Pharmaceuticals in Q1 2023 and held it in 1 quarter.
LMR Partners's Verrica Pharmaceuticals position peaked at $86.1K in Q1 2023.
63 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.